COLL
COLLEGIUM PHARMACEUTICAL, INC
$34.09
-0.38%
$1.1B
No data for this timeframe.
Vol
Market Cap$1.1B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders9 funds
Inst. Value$268.4M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 7S
Insider Net $-$3.2M
SEC Reports6
Press Releases3
Recent Activity
May 18, 2026
SEC
Two directors at Collegium Pharmaceutical sold a combined $485K in open-market stock within 11 days of the company repor
CLUSTER — Impact 3/10
May 18, 2026
Insider
Freund John Gordon sold 20 shares
Director @ $34.05 ($681.00)
May 15, 2026
Insider
Freund John Gordon sold 8,700 shares
Director @ $16.49 ($143.5K)
May 15, 2026
Insider
Freund John Gordon sold 4,127 shares
Director @ $34.54 ($142.5K)
May 12, 2026
Press
Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 mil
Impact 7/10
May 12, 2026
m_and_a
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
<p align="center"><em>– Adds Highly Complementary and Differentiated Medicine with Significant Growt
May 11, 2026
SEC
Director Garen G. Bohlin filed a Form 144 notice of intent to sell 8,700 shares of Collegium Pharmaceutical common stock
144 — Impact 2/10
Apr 23, 2026
SEC
Collegium Pharmaceutical announced it will report Q1 2026 financial results on May 7, 2026, followed by a conference cal
PRESS-RELEASE — Impact 2/10
Price Targets
$54.33
+59.4% upside
Strong Buy
Current $34.09
Low $45.00
Median $56.00
High $60.00
6 analysts
$45.00
$60.00
Analyst Ratings
3Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 19, 2026 | Needham | REITERATE | Buy → Buy |
| Feb 26, 2026 | Needham | MAINTAIN | Buy → Buy |
| Jan 9, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.72 ▼ -1.5% | $1.62 — $1.81 | 3% YoY | 5 |
| Next Q | $2.08 ▲ +8.1% | $1.93 — $2.32 | -8% YoY | 5 |
| Current FY | $7.72 ▲ +5.8% | $7.29 — $8.25 | 4% YoY | 5 |
| Next FY | $7.61 ▲ +19.1% | $5.66 — $9.28 | -1% YoY | 5 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Two directors at Collegium Pharmaceutical sold a combined $485K in open-market stock within 11 days of the company repor
May 18, 2026
BULLISH
Press
7/10
Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 mil
May 12, 2026
NEUTRAL
144
2/10
Director Garen G. Bohlin filed a Form 144 notice of intent to sell 8,700 shares of Collegium Pharmaceutical common stock
May 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $104.5M | — |
| RENAISSANCE TECHNOLOGIES LLC | $74.9M | — |
| MORGAN STANLEY | $31.7M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $20.7M | NEW |
| TWO SIGMA INVESTMENTS, LP | $17.0M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Freund John | SELL | $681.00 |
| May 15, 2026 | Freund John | M | $143.5K |
| May 15, 2026 | Freund John | SELL | $142.5K |
| May 15, 2026 | Freund John | M | $0.00 |
| May 14, 2026 | Freund John | A | $0.00 |
9 institutional holders with $268.4M total value (5,796,892 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,256,254 | $104.5M | 38.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,617,349 | $74.9M | 27.9% | — |
| 3 | MORGAN STANLEY | 684,613 | $31.7M | 11.8% | ADD +25.0% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 447,282 | $20.7M | 7.7% | NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 366,099 | $17.0M | 6.3% | ADD +35.9% |
| 6 | BANK OF AMERICA CORP /DE/ | 195,345 | $9.0M | 3.4% | TRIM -52.3% |
| 7 | NORGES BANK | 112,500 | $5.2M | 1.9% | NEW |
| 8 | FMR LLC | 59,862 | $2.8M | 1.0% | — |
| 9 | WELLS FARGO & COMPANY/MN | 57,588 | $2.7M | 1.0% | DOUBLED +157.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 269,318 | 366,099 | +35.9% | $17.0M | 2025-Q4 |
| NORGES BANK | NEW | — | 112,500 | — | $5.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 22,366 | 57,588 | +157.5% | $2.7M | 2025-Q4 |
| MORGAN STANLEY | ADD | 613,826 | 767,420 | +25.0% | $26.9M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 27,008 | 269,318 | +897.2% | $9.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 514,807 | 245,768 | -52.3% | $8.6M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 17,664 | 22,366 | +26.6% | $782.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 75,224 | 27,008 | -64.1% | $798.6K | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 380,071 | 522,455 | +37.5% | $15.6M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 162,144 | 380,071 | +134.4% | $10.9M | 2024-Q4 |
| UBS Group AG | DOUBLED | 36,221 | 200,517 | +453.6% | $5.7M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 30,606 | 20,619 | -32.6% | $590.7K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 381,494 | — | $14.7M | 2024-Q3 |
12 unique insiders with 7 transactions. Net insider value: -$3.2M ($0.00 bought, $3.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Freund John Gordon | Director | SELL | 20 | $34.05 | $681.00 |
| May 15, 2026 | Freund John Gordon | Director | M | 8,700 | $16.49 | $143.5K |
| May 15, 2026 | Freund John Gordon | Director | SELL | 4,127 | $34.54 | $142.5K |
| May 15, 2026 | Freund John Gordon | Director | M | 8,700 | $0.00 | $0.00 |
| May 14, 2026 | Freund John Gordon | Director | A | 8,741 | $0.00 | $0.00 |
| May 14, 2026 | Glancy Donovan Michael | Director | A | 17,482 | $0.00 | $0.00 |
| May 14, 2026 | SANTINI GINO | Director | A | 8,741 | $0.00 | $0.00 |
| May 14, 2026 | Lurker Nancy | Director | A | 8,741 | $0.00 | $0.00 |
| May 14, 2026 | Balice-Gordon Rita J. | Director | A | 8,741 | $0.00 | $0.00 |
| May 14, 2026 | Paya Carlos V | Director | A | 8,741 | $0.00 | $0.00 |
| May 14, 2026 | BOHLIN GAREN G | Director | A | 8,741 | $0.00 | $0.00 |
| May 13, 2026 | Lurker Nancy | Director | SELL | 4,500 | $35.97 | $161.9K |
| May 11, 2026 | BOHLIN GAREN G | Director | M | 8,700 | $16.49 | $143.5K |
| May 11, 2026 | BOHLIN GAREN G | Director | SELL | 8,700 | $37.18 | $323.5K |
| May 11, 2026 | BOHLIN GAREN G | Director | M | 8,700 | $0.00 | $0.00 |
| Mar 18, 2026 | Dieter David | EVP & General Counsel | SELL | 13,976 | $34.92 | $488.1K |
| Mar 17, 2026 | Dieter David | EVP & General Counsel | F | 8,840 | $35.72 | $315.8K |
| Mar 9, 2026 | Dieter David | EVP & General Counsel | SELL | 6,224 | $36.65 | $228.1K |
| Mar 3, 2026 | Dreyer Scott | EVP & Chief Commercial Officer | SELL | 46,417 | $40.36 | $1.9M |
| Feb 10, 2026 | Smith Thomas B | EVP and Chief Medical Officer | A | 14,268 | $0.00 | $0.00 |
| Feb 10, 2026 | Smith Thomas B | EVP and Chief Medical Officer | F | 5,897 | $46.75 | $275.7K |
| Feb 10, 2026 | Tupper Colleen | EVP & Chief Financial Officer | A | 26,421 | $0.00 | $0.00 |
| Feb 10, 2026 | Tupper Colleen | EVP & Chief Financial Officer | F | 11,861 | $46.75 | $554.5K |
| Feb 10, 2026 | Dieter David | EVP & General Counsel | A | 22,194 | $0.00 | $0.00 |
| Feb 10, 2026 | Dieter David | EVP & General Counsel | F | 2,781 | $46.75 | $130.0K |
| Feb 10, 2026 | Dreyer Scott | EVP & Chief Commercial Officer | A | 19,023 | $0.00 | $0.00 |
| Feb 10, 2026 | Dreyer Scott | EVP & Chief Commercial Officer | F | 9,977 | $46.75 | $466.4K |
| Feb 10, 2026 | Karnani Vikram | President and CEO | A | 79,264 | $0.00 | $0.00 |
| Feb 10, 2026 | Karnani Vikram | President and CEO | F | 11,296 | $46.75 | $528.1K |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.5/10.
NEUTRAL
CLUSTER
3/10
Two directors at Collegium Pharmaceutical sold a combined $485K in open-market stock within 11 days
May 18, 2026
NEUTRAL
144
2/10
Director Garen G. Bohlin filed a Form 144 notice of intent to sell 8,700 shares of Collegium Pharmac
May 11, 2026
NEUTRAL
PRESS-RELEASE
2/10
Collegium Pharmaceutical announced it will report Q1 2026 financial results on May 7, 2026, followed
Apr 23, 2026
NEUTRAL
8-K
3/10
Collegium Pharmaceutical announced the nomination of Michael Donovan to its board of directors and t
Apr 7, 2026
NEUTRAL
CLUSTER
4/10
EVP & General Counsel Dieter David sold 6,224 shares in an open-market transaction for approximately
Mar 11, 2026
BULLISH
8-K
7/10
Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2025, with revenue g
Feb 26, 2026
BULLISH
7/10
Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Thera
May 12, 2026
BULLISH
8/10
Collegium Pharmaceutical is acquiring AZSTARYS, a differentiated ADHD treatment, from Corium Therape
Mar 19, 2026
NEUTRAL
3/10
Collegium Pharmaceutical announced a partnership with Paris Hilton on a public awareness campaign ca
Mar 3, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 3 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$54.33 mean target
+59.4% upside
Strong Buy (1.67)
$45.00 Low
$60.00 High
| Metric | Value |
|---|---|
| Current Price | $34.09 |
| Target Low | $45.00 |
| Target Mean | $54.33 |
| Target Median | $56.00 |
| Target High | $60.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.72 | $1.62 | $1.81 | 2.5% | -1.5% | 2↑ 3↓ | $0.2B | 7.1% | 5 |
| Next Q 2026-09-30 |
$2.08 | $1.93 | $2.32 | -7.7% | +8.1% | 5↑ 0↓ | $0.2B | 12.2% | 5 |
| Current FY 2026-12-31 |
$7.72 | $7.29 | $8.25 | 4.0% | +5.8% | 4↑ 1↓ | $0.9B | 12.0% | 5 |
| Next FY 2027-12-31 |
$7.61 | $5.66 | $9.28 | -1.4% | +19.1% | 5↑ 0↓ | $0.9B | 1.3% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.722 | |
| 7d ago | $1.709 | +0.013 |
| 30d ago | $1.749 | -0.027 |
| 60d ago | $1.823 | -0.101 |
| 90d ago | $1.803 | -0.081 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 19, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 8, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 9, 2025 | Barclays | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Jan 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
m_and_a
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
<p align="center"><em>– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio
May 7, 2026
earnings
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
<p align="center"><em>– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – </em></p>
May 7, 2026
earnings_calendar
COLL Q1 2026 Earnings Scheduled — 2026-05-07
Apr 23, 2026
earnings
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
<p>STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KfCZr-RgrwXz3mxbDe7aDqdbs6dpPoRZ3EygQCLC
Mar 19, 2026
m_and_a
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
<p align="center"><em>– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio
Mar 5, 2026
routine
Collegium to Present New Real-World Data at PainConnect 2026
<p>STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=DuuAb9QZsaKy5bGGZ5IaYYvmPa78ziqkttHFUoNz
Mar 3, 2026
contract
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
<p align="center"><em>– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light </em>–</p>
Feb 26, 2026
earnings_calendar
COLL Q4 2025 Earnings Before Market Open — 2026-02-26